An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Clinical trial NCT07206056 · RECRUITING
Trial details
- NCT number
- NCT07206056
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-15
- Primary completion
- 2029-11-09
- Enrollment
- 188
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.